Practical guide for oncologists to manage patient expectations around 'breakthrough' cancer drugs using a structured conversation and clear risk-benefit numbers.
2 articles found in 0.95s
Practical guide for oncologists to manage patient expectations around 'breakthrough' cancer drugs using a structured conversation and clear risk-benefit numbers.
Learn why FDA 'breakthrough' therapy designation often reflects expedited review, not proven clinical benefit, how to interpret evidence and avoid hype.